Shares of Bayer AG (NASDAQ:BAYRY) have been assigned an average recommendation of “Buy” from the six ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating and five have issued a buy rating on the company.

BAYRY has been the topic of a number of recent research reports. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Bayer AG in a research report on Friday, February 24th. Zacks Investment Research upgraded Bayer AG from a “sell” rating to a “hold” rating in a research note on Tuesday, March 21st.

Bayer AG (NASDAQ:BAYRY) opened at 137.84 on Monday. The company has a market cap of $120.11 billion and a PE ratio of 20.49. Bayer AG has a 52-week low of $91.53 and a 52-week high of $137.87. The firm’s 50-day moving average price is $130.26 and its 200 day moving average price is $114.89.

Bayer AG (NASDAQ:BAYRY) last issued its quarterly earnings results on Thursday, April 27th. The company reported $2.80 EPS for the quarter, beating analysts’ consensus estimates of $2.40 by $0.40. The firm had revenue of $14.11 billion for the quarter, compared to analysts’ expectations of $13.65 billion. On average, equities analysts predict that Bayer AG will post $8.95 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Bayer AG (BAYRY) Given Average Recommendation of “Buy” by Analysts” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at

Bayer AG Company Profile

Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.

Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with's FREE daily email newsletter.